Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tony R Reid

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Journal for Immunotherapy of Cancer|October 26, 2024
TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistanceTony R Reid, Bryan Oronsky, Jeannie Williams, et al.
Seminars in Oncology|July 29, 2020
Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19Bryan Oronsky, Susan Knox, Pedro Cabrales, et al.
Frontiers in Oncology|February 22, 2021
A Review of Newly Diagnosed GlioblastomaBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
American Journal of Cancer Research|November 12, 2021
Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-betaChristopher Larson, Bryan Oronsky, Nacer E Abrouk, et al.
Future Oncology (London, England)|August 8, 2008
Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancerMeghana Trivedi, Imawati Budihardjo, Kirsten Loureiro, et al.
Cancer Gene Therapy|April 2, 2005
Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorinTony R Reid, Scott Freeman, Leonard Post, et al.
Journal for Immunotherapy of Cancer|June 17, 2024
Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believingAnthony Conley, Christopher Larson, Bryan Oronsky, et al.
Gastrointestinal Endoscopy|April 30, 2002
A novel method to control severe upper GI bleeding from metastatic cancer with a hemostatic sealant: the CoStasis surgical hemostatDavid E Milkes, Shai Friedland, Otto S Lin, et al.
Oncoimmunology|January 18, 2021
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"Bryan Oronsky, Corey A Carter, Scott Caroen, et al.
Oncotarget|May 29, 2018
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cellsBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Journal for Immunotherapy of Cancer|October 26, 2024
TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistanceTony R Reid, Bryan Oronsky, Jeannie Williams, et al.
Seminars in Oncology|July 29, 2020
Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19Bryan Oronsky, Susan Knox, Pedro Cabrales, et al.
Frontiers in Oncology|February 22, 2021
A Review of Newly Diagnosed GlioblastomaBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
American Journal of Cancer Research|November 12, 2021
Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-betaChristopher Larson, Bryan Oronsky, Nacer E Abrouk, et al.
Future Oncology (London, England)|August 8, 2008
Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancerMeghana Trivedi, Imawati Budihardjo, Kirsten Loureiro, et al.
Cancer Gene Therapy|April 2, 2005
Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorinTony R Reid, Scott Freeman, Leonard Post, et al.
Journal for Immunotherapy of Cancer|June 17, 2024
Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believingAnthony Conley, Christopher Larson, Bryan Oronsky, et al.
Gastrointestinal Endoscopy|April 30, 2002
A novel method to control severe upper GI bleeding from metastatic cancer with a hemostatic sealant: the CoStasis surgical hemostatDavid E Milkes, Shai Friedland, Otto S Lin, et al.
Oncoimmunology|January 18, 2021
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"Bryan Oronsky, Corey A Carter, Scott Caroen, et al.
Oncotarget|May 29, 2018
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cellsBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Pageof 6